Randomized Phase II Trial Evaluating the Addition of the IGF-1R Monoclonal Antibody Ganitumab (AMG 479 NSC# 750008) to Multiagent Chemotherapy for Patients With Newly Diagnosed Metastatic Ewing Sarcoma
This randomized phase II trial studies how well combination chemotherapy with or without ganitumab works in treating patients with newly diagnosed Ewing sarcoma that has spread to other parts of the body.
The purpose of this study is to compare the event-free survival (EFS) in patients with newly diagnosed metastatic Ewing sarcoma treated with multiagent chemotherapy with and without the addition of ganitumab (AMG 479).
- IRB Number: 1412135386 (PHO-COG-FALLON-AEWS1221)
- Research Study Identifier: TX4665
- Principal Investigator: Kamnesh Pradhan, MD
Contact the research team to learn more about this study.
Fields marked with asterisk (*) are required